101
|
Bose P, Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 2010; 18:1735-51. [PMID: 19780706 DOI: 10.1517/13543780903305428] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
BACKGROUND The revolutionary success of imatinib, a specific inhibitor of the BCR-ABL tyrosine kinase (TK) in the treatment of chronic myelogenous leukemia ushered in the era of targeted therapies in cancer. The erythroblastic leukemia viral oncogene homolog family of receptor TKs, to which EGFR (HER1) and human epidermal growth factor receptor 2 (HER2)/neu TKs belong, has been implicated in a variety of cancers, and several agents that inhibit these TKs are in clinical use, with many more in various stages of development. OBJECTIVES To summarize current knowledge about neratinib (HKI-272), an oral, irreversible dual inhibitor of EGFR and HER2 and to define its future clinical role, especially in the context of related agents that are either available or in the pipeline. METHODS A Medline search using Pubmed was conducted using the keywords neratinib, HKI-272, EGFR, HER2, lapatinib, trastuzumab, erlotinib, gefitinib, cetuximab and panitumumab. Relevant abstracts presented at the American Society of Clinical Oncology and San Antonio Breast Cancer Symposium meetings were also reviewed. CONCLUSIONS Both preclinical and human studies have shown that neratinib has promising activity in both advanced breast cancer and NSCLC with an acceptable safety profile. The data support its continued clinical development.
Collapse
Affiliation(s)
- Prithviraj Bose
- Department of Internal Medicine, Section of Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
| | | |
Collapse
|
102
|
Frampton JE. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 2010; 69:2125-48. [PMID: 19791830 DOI: 10.2165/11203240-000000000-00000] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Lapatinib (Tyverb, Tykerb) is an orally active, small molecule, reversible, dual tyrosine kinase inhibitor of human epidermal growth factor receptor type 1 (HER1) and type 2 (HER2). In the EU, lapatinib in combination with capecitabine is indicated for the treatment of women with HER2-overexpressing, advanced or metastatic breast cancer that has progressed after treatment with regimens that include anthracyclines, taxanes and, in the metastatic setting, trastuzumab. The orally administered combination of lapatinib and capecitabine was a more effective treatment than capecitabine alone, and was a generally well tolerated, conveniently administered combination for women with trastuzumab-refractory, HER2-positive advanced or metastatic breast cancer in a clinical trial. Lapatinib combined with capecitabine provides an effective therapeutic option for a group of patients who currently have few treatment choices.
Collapse
|
103
|
Abstract
The human epidermal growth factor receptor (HER) family of growth factor receptor tyrosine kinases (RTKs) plays an important role in the biology of many cancers. In breast cancer, HER2 and its homo- or heterodimerization with HER1 or HER3 are essential for cancer cell growth and survival. Patients overexpressing HER2 have a poor prognosis, which can be substantially improved upon HER2-targeted therapy using the monoclonal antibody trastuzumab. Lapatinib is a novel dual tyrosine kinase inhibitor, blocking HER1 and HER2 tyrosine kinase activity by binding to the ATP-binding site of the receptor's intracellular domain. This results in inhibition of tumor cell growth. The drug is relatively well tolerated in patients, with few and mostly low-grade adverse effects. In particular and unlike to trastuzumab, it has very little, if any, adverse effects on cardiac function. In patients with advanced HER2-positive breast cancer, lapatinib has shown substantial antitumor activity, particularly in combination with capecitabine upon progressive disease following standard therapy with antracyclines, taxanes, and trastuzumab. Ongoing and future studies will explore its role in the adjuvant therapy setting, in drug combinations other than capecitabine, and in the treatment of HER2-positive tumors other than breast cancer.
Collapse
Affiliation(s)
- Tanja Schneider-Merck
- Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
| | | |
Collapse
|
104
|
Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2009; 7:98-107. [DOI: 10.1038/nrclinonc.2009.216] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
105
|
Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. ACTA ACUST UNITED AC 2009; 7:263-274. [PMID: 20300449 DOI: 10.2174/187569209790112337] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
HER2 is over-expressed in approximately 25% to 30% of human metastatic breast cancers, primarily due to gene amplification. There are currently two HER2-targeted therapies approved for clinical use, the monoclonal HER2 antibody trastuzumab and the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. Although both agents show clinical benefit in a subset of patients with metastatic breast cancer, many patients with HER2-over-expressing metastatic breast tumors do not respond to these agents. Furthermore, those who do show an initial response generally demonstrate disease progression, on average in less than one year. It has become clear that HER2 expression status alone does not adequately predict response to HER2-targeted therapy. Identification and clinical validation of molecular predictors of response to trastuzumab and lapatinib is critical for further personalizing treatment and improving clinical benefit for patients whose tumors over-express HER2. In this review, we discuss published data describing potential predictors of response or resistance to trastuzumab and lapatinib. While a discussion of the preclinical work is provided, the emphasis is placed on potential predictors that have been studied in clinical specimens such as tumor tissue or serum obtained from patients treated with HER2-targeted therapy. The present analysis and synthesis of the available literature therefore contribute towards an emerging knowledgebase to personalize breast cancer treatment taking into factors including but beyond HER2 expression.
Collapse
Affiliation(s)
- R Nahta
- Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322
| | | | | | | |
Collapse
|
106
|
Abstract
Remarkable progress has been made in the treatment of breast cancer over the past 100 years. The ability to probe at the genomic level increased our understanding of the disease but the improved survival outcomes can also be attributed to screening programs, which have altered the pattern of diagnosis and prognosis, and to a number of groundbreaking clinical trials. Indeed, the latter are largely responsible for the most startling paradigm reversals in oncology; namely, that optimal benefit can be achieved with minimal, rather than maximal, intervention. As such, surgical lumpectomy can replace the radical mastectomy, sentinel node biopsy may circumvent the need for complete (axillary) nodal dissection, hormonal therapy--depending on tumor sensitivity to endocrine manipulation--is likely to be beneficial without the addition of chemotherapy, and some targeted therapies can be used selectively in those most likely to benefit. However, despite the advances, controversies remain; patients die; and cure remains elusive.
Collapse
Affiliation(s)
- Gerald M Higa
- West Virginia University, Mary Babb Randolph Cancer Center, Schools of Pharmacy and Medicine, Morgantown, WV 26506-9520, USA.
| |
Collapse
|
107
|
Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res 2009; 15:6921-30. [PMID: 19903791 DOI: 10.1158/1078-0432.ccr-09-1599] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
PURPOSE Resistance to anti-HER2 monoclonal antibody trastuzumab is a relevant issue in breast cancer patients. Among the mechanisms implicated in trastuzumab resistance, increasing evidence supports a role of tumor microenvironment. We previously found that a novel toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, acts through epidermal growth factor receptor (EGFR) and shows direct antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF drugs, thus interfering with cancer cells and microenvironment. EXPERIMENTAL DESIGN In this study, we used KPL-4 and JIMT-1 trastuzumab-resistant breast cancer cells to evaluate the combination IMO plus trastuzumab as a therapeutic option for trastuzumab-resistant breast cancers. RESULTS IMO inhibits KPL-4 and JIMT-1 xenografts growth and potentiates trastuzumab antitumor effect, with complete suppression of tumor growth, potent enhancement of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity, and strong inhibition of EGFR/HER2-related signaling. In KPL-4 xenografts, IMO alone interferes with HER signal transduction, whereas trastuzumab is ineffective. IMO induces an HER-dependent signal inhibition also in vitro by modulating a functional interaction between toll-like receptor 9 and HER receptors occurring at membrane level. Finally, IMO plus trastuzumab produces a cooperative antiangiogenic effect related to suppression of endothelial HER-related signaling. CONCLUSIONS We showed a cooperative effect of IMO plus trastuzumab in trastuzumab-resistant breast cancers due to IMO direct antitumor and antiangiogenic activity and antibody-dependent cell-mediated cytotoxicity enhancement. Moreover, we provided first evidence of a toll-like receptor 9/HER interaction at membrane level as novel mechanism of action. Altogether, we propose IMO plus trastuzumab as an effective strategy in trastuzumab-resistant breast cancers.
Collapse
Affiliation(s)
- Vincenzo Damiano
- Departments of Endocrinologia ed Oncologia Molecolare e Clinica, and Biologia e Patologia Cellulare e Molecolare L. Califano, Università di Napoli Federico II, Napoli, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
108
|
Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009; 27:5838-47. [PMID: 19884552 DOI: 10.1200/jco.2009.22.1507] [Citation(s) in RCA: 356] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
PURPOSE Targeted therapy with the humanized monoclonal antibody trastuzumab has become a mainstay for human epidermal growth factor receptor 2 (HER2) -positive breast cancer (BC). The mechanisms of action of trastuzumab have not been fully elucidated, and data available to date are reviewed here. The impact of the mechanisms of action on clinical benefit also is discussed. METHODS An extensive literature review of trastuzumab and proposed mechanisms of action was performed. RESULTS At least five potential extracellular and intracellular antitumor mechanisms of trastuzumab have been identified in the preclinical setting. These include activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domain cleavage, abrogation of intracellular signaling, reduction of angiogenesis, and decreased DNA repair. These effects lead to tumor cell stasis and/or death. Clinical benefit from trastuzumab-based therapy in both early and advanced BC has been demonstrated. The benefit of trastuzumab use beyond progression has also been shown, which indicates the need for continuous suppression of the HER2 pathway. Targeting both HER2, with various approaches, and other pathways may enhance the clinical benefit observed with trastuzumab and overcome potential resistance. Novel combinations include pertuzumab (a HER2 dimerization inhibitor), lapatinib (a HER1/HER2 tyrosine kinase inhibitor), bevacizumab (an antiangiogenic agent), tanespimycin (a heat shock protein inhibitor), antiestrogen therapies, and an antibody-drug conjugate (trastuzumab-DM1). CONCLUSION Trastuzumab is the foundation of care for patients with HER2-positive BC. Emerging data from studies of other targeted agents may provide alternative treatment combinations to maximize the clinical benefit from trastuzumab and prevent or delay resistance. The continued development of trastuzumab highlights promising treatment approaches for the future.
Collapse
Affiliation(s)
- Neil L Spector
- Duke Translational Research Oncology Program, Duke University Hospital, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA.
| | | |
Collapse
|
109
|
Collins D, Hill A, Young L. Lapatinib: A competitor or companion to trastuzumab? Cancer Treat Rev 2009; 35:574-81. [DOI: 10.1016/j.ctrv.2009.06.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2009] [Revised: 06/09/2009] [Accepted: 06/11/2009] [Indexed: 12/01/2022]
|
110
|
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2009; 29:325-34. [PMID: 19855434 PMCID: PMC3057066 DOI: 10.1038/onc.2009.337] [Citation(s) in RCA: 99] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The anti-HER2 antibody Trastuzumab (Herceptin) has been proven to be effective in the treatment of HER2 overexpressing breast cancer; resistance, however invariably emerges in metastatic tumors. The expression of p95-HER2, a form of HER2 with a truncated extracellular domain that lacks the Trastuzumab binding epitope, has been implicated as a mechanism of resistance to the antibody. We utilized an in vivo tumor model that overexpresses p95-HER2 and demonstrate it to be resistant to the signaling and antitumor effects of Trastuzumab. We find that both full length and p95-HER2 interact with the HSP90 chaperone protein and are degraded in tumor cells exposed to HSP90 inhibitors in tissue culture and in vivo. Loss of expression of p95-HER2 is accompanied by downregulation of the PI3K/AKT and ERK signaling pathways and inhibition of cell proliferation. Chronic administration of HSP90 inhibitors in vivo results in sustained loss of HER2 and p95-HER2 expression and inhibition of AKT activation together with induction of apoptosis and complete inhibition of tumor growth in Trastuzumab-resistant, p95-HER2-overexpressing models. Thus, p95-HER2 is an HSP90 client protein, the expression and function of which can be effectively suppressed in vivo by HSP90 inhibitors. HSP90 inhibition is therefore a potentially effective therapeutic strategy for p95-HER2-mediated Trastuzumab-resistant breast cancer.
Collapse
|
111
|
Milanezi F, Leitão D, Ricardo S, Augusto I, Schmitt F. Evaluation of HER2 in breast cancer: reality and expectations. ACTA ACUST UNITED AC 2009; 3:607-20. [PMID: 23496046 DOI: 10.1517/17530050903222221] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
BACKGROUND The introduction of drugs, whose mechanisms of action are directed against specific molecules involved in cancer initiation and/or progression, has changed the daily workup of breast cancer patients. At present, HER2 expression and/or amplification should be evaluated in every primary invasive breast cancer either at the time of diagnosis or at the time of recurrence, mostly to guide selection of trastuzumab in the adjuvant and/or metastatic setting. The adequate selection of patients is an essential step for indication of anti-HER2 therapy. OBJECTIVE This review focuses on the state of the art for HER2 evaluation in breast cancer, as well as expectations regarding future molecular assays based on mechanisms of resistance to HER2-driven therapy. METHODS Data were obtained by searching the PubMed database, including the terms 'HER2', 'in situ hybridisation', 'immunohistochemistry', 'trastuzumab', 'breast cancer', 'therapy', 'resistance' and 'tyrosine-kinase inhibitors', with a preference for updated publications. CONCLUSION Pathologists have a central role in the selection of patients who will benefit from anti-HER-based therapies, with a responsibility to obtain the most reliable results for immunohistochemistry and in situ hybridisation techniques. Pre-analytical variables, such as type of fixative and time of fixation, are critical to guarantee consistent and quality assays, as well as to facilitate interpretation and decrease interobserver variability. Rigorous quality control and centralisation of techniques/interpretation of results are recommended to guarantee consistent assays.
Collapse
Affiliation(s)
- Fernanda Milanezi
- Institute of Molecular Pathology and Immunology of Porto University, Rua Roberto Frias, s/n, 4200-465, Porto, Portugal +351 225570700 ; +351 225570799 ;
| | | | | | | | | |
Collapse
|
112
|
Riera R, Soárez PCD, Puga MEDS, Ferraz MB. Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. SAO PAULO MED J 2009; 127:295-301. [PMID: 20169279 DOI: 10.1590/s1516-31802009000500009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2009] [Accepted: 11/18/2009] [Indexed: 11/22/2022] Open
Abstract
CONTEXT AND OBJECTIVE Around 16% to 20% of women with breast cancer have advanced, metastasized breast cancer. At this stage, the disease is treatable, but not curable. The objective here was to assess the effectiveness of lapatinib for treating patients with advanced or metastasized breast cancer. DESIGN AND SETTING Systematic review of the literature, developed at Centro Paulista de Economia da Saúde (CPES), Universidade Federal de São Paulo (Unifesp). METHOD Systematic review with searches in virtual databases (PubMed, Lilacs [Literatura Latino-Americana e do Caribe em Ciências da Saúde], Cochrane Library, Scirus and Web of Science) and manual search. RESULTS Only one clinical trial that met the selection criteria was found. This study showed that lapatinib in association with capecitabine reduced the risk of cancer progression by 51% (95% confidence interval, CI: 0.34-0.71; P < 0.001), compared with capecitabine alone, without any increase in severe adverse effects. CONCLUSION The combination of lapatinib plus capecitabine was more effective than capecitabine alone for reducing the risk of cancer progression. Further randomized clinical trials need to be carried out with the aim of assessing the effectiveness of lapatinib as monotherapy or in association for first-line or second-line treatment of advanced breast cancer.
Collapse
Affiliation(s)
- Rachel Riera
- Centro Paulista de Economia da Saúde, Vila Clementino, São Paulo (SP), Brazil.
| | | | | | | |
Collapse
|
113
|
Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2–positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Mol Cancer Ther 2009; 8:2131-41. [DOI: 10.1158/1535-7163.mct-08-1038] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
114
|
Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2009; 21:255-262. [PMID: 19633047 DOI: 10.1093/annonc/mdp304] [Citation(s) in RCA: 167] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND The mechanism of resistance to human epidermal growth factor receptor 2 (HER2)-targeted agents has not been fully understood. We investigated the influence of PIK3CA mutations on sensitivity to HER2-targeted agents in naturally derived breast cancer cells. MATERIALS AND METHODS We examined the effects of Calbiochem (CL)-387,785, HER2 tyrosine kinase inhibitor, and trastuzumab on cell growth and HER2 signaling in eight breast cancer cell lines showing HER2 amplification and trastuzumab-conditioned BT474 (BT474-TR). RESULTS Four cell lines with PIK3CA mutations (E545K and H1047R) were more resistant to trastuzumab than the remaining four without mutations (mean percentage of control with 10 microg/ml trastuzumab: 58% versus 92%; P = 0.010). While PIK3CA-mutant cells were more resistant to CL-387,785 than PIK3CA-wild-type cells (mean percentage of control with 1 microM CL-387,785: 21% versus 77%; P = 0.001), CL-387,785 retained activity against BT474-TR. Growth inhibition by trastuzumab and CL-387,785 was more closely correlated with changes in phosphorylation of S6K (correlation coefficient, 0.811) than those of HER2, Akt, or ERK1/2. Growth of most HER2-amplified cells was inhibited by LY294002, regardless of PIK3CA genotype. CONCLUSIONS PIK3CA mutations are associated with resistance to HER2-targeted agents. PI3K inhibitors are potentially effective in overcoming trastuzumab resistance caused by PIK3CA mutations. S6K phosphorylation is a possibly useful pharmacodynamic marker in HER2-targeted therapy.
Collapse
Affiliation(s)
| | - T Mukohara
- Cancer Center, Kobe University Hospital; Medical Oncology, Department of Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe.
| | - H Shimada
- Research Center for Innovative Oncology, National Cancer Hospital East, Kashiwa, Japan
| | - N Saijo
- Research Center for Innovative Oncology, National Cancer Hospital East, Kashiwa, Japan
| | | | - H Minami
- Cancer Center, Kobe University Hospital; Medical Oncology, Department of Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe
| |
Collapse
|
115
|
|
116
|
Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, Lee JH, Oh DY, Im SA, Bang YJ, Kim TY. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 2009; 4:e5933. [PMID: 19529774 PMCID: PMC2691960 DOI: 10.1371/journal.pone.0005933] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2009] [Accepted: 05/06/2009] [Indexed: 11/19/2022] Open
Abstract
Background Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been shown to exert a synergistic antitumor effect when combined with fluoropyrimidine. This synergy may be attributable to the downregulation of thymidylate synthase (TS), which is frequently overexpressed in fluoropyrimidine-resistant cancer cells. However, the molecular mechanism underlying the downregulation of TS has yet to be clearly elucidated. Methodology and Principal Findings In this study, we demonstrate that lapatinib, a dual TKI of EGFR and HER2 downregulates TS via inhibition of the nuclear translocation of EGFR and HER2. From our cDNA microarray experiments, we determined that a variety of nucleotide synthesis-related genes, including TS, were downregulated with lapatinib, and this was apparent in HER2-amplified cells. Targeted and pharmacologic inhibition assays confirmed that the dual inhibition of EGFR and HER2 is required for the more effective reduction of TS as compared to what was observed with gefitinib or trasutuzumab alone. Additionally, we determined that co-transfected EGFR and HER2 activate the TS gene promoter more profoundly than do either EGFR or HER2 alone. The translocation of EGFR and HER2 into the nucleus and the subsequent activation of the TS promoter were inhibited by lapatinib. Conclusions and Significance These results demonstrate that lapatinib inhibits the nuclear translocation of EGFR and HER2 and downregulates TS, thus sensitizing cancer cells to fluoropyrimidine.
Collapse
Affiliation(s)
- Hwang-Phill Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Young-Kwang Yoon
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Jin-Won Kim
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Sae-Won Han
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Hyung-Seok Hur
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Jinah Park
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Ju-Hee Lee
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
| | - Do-Youn Oh
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Seock-Ah Im
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Yung-Jue Bang
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
| | - Tae-You Kim
- Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
- * E-mail:
| |
Collapse
|
117
|
Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res 2009; 15:4147-56. [PMID: 19509167 DOI: 10.1158/1078-0432.ccr-08-2814] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
PURPOSE Oncogenic activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is prevalent in breast cancer and has been associated with resistance to HER2 inhibitors in the clinic. We therefore investigated the combinatorial activity of GDC-0941, a novel class I PI3K inhibitor, with standard-of-care therapies for HER2-amplified breast cancer. EXPERIMENTAL DESIGN Three-dimensional laminin-rich extracellular matrix cultures of human breast cancer cells were utilized to provide a physiologically relevant approach to analyze the efficacy and molecular mechanism of combination therapies ex vivo. Combination studies were done using GDC-0941 with trastuzumab (Herceptin), pertuzumab, lapatinib (Tykerb), and docetaxel, the principal therapeutic agents that are either approved or being evaluated for treatment of early HER2-positive breast cancer. RESULTS Significant GDC-0941 activity (EC(50) <1 micromol/L) was observed for >70% of breast cancer cell lines that were examined in three-dimensional laminin-rich extracellular matrix culture. Differential responsiveness to GDC-0941 as a single agent was observed for luminal breast cancer cells upon stimulation with the HER3 ligand, heregulin. Combined treatment of GDC-0941, trastuzumab, and pertuzumab resulted in growth inhibition, altered acinar morphology, and suppression of AKT mitogen-activated protein kinase (MAPK) / extracellular signed-regulated kinase (ERK) kinase and MEK effector signaling pathways for HER2-amplified cells in both normal and heregulin-supplemented media. The GDC-0941 and lapatinib combination further showed that inhibition of HER2 activity was essential for maximum combinatorial efficacy. PI3K inhibition also rendered HER2-amplified BT-474M1 cells and tumor xenografts more sensitive to docetaxel. CONCLUSIONS GDC-0941 is efficacious in preclinical models of breast cancer. The addition of GDC-0941 to HER2-directed treatment could augment clinical benefit in breast cancer patients.
Collapse
Affiliation(s)
- Evelyn Yao
- Department of Cancer Signaling, Genentech, Inc, South San Francisco, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
118
|
|
119
|
A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009; 29:3319-31. [PMID: 19364815 DOI: 10.1128/mcb.01803-08] [Citation(s) in RCA: 131] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
HER2 is a tyrosine kinase receptor causally involved in cancer. A subgroup of breast cancer patients with particularly poor clinical outcomes expresses a heterogeneous collection of HER2 carboxy-terminal fragments (CTFs). However, since the CTFs lack the extracellular domain that drives dimerization and subsequent activation of full-length HER2, they are in principle expected to be inactive. Here we show that at low expression levels one of these fragments, 611-CTF, activated multiple signaling pathways because of its unanticipated ability to constitutively homodimerize. A transcriptomic analysis revealed that 611-CTF specifically controlled the expression of genes that we found to be correlated with poor prognosis in breast cancer. Among the 611-CTF-regulated genes were several that have previously been linked to metastasis, including those for MET, EPHA2, matrix metalloproteinase 1, interleukin 11, angiopoietin-like 4, and different integrins. It is thought that transgenic mice overexpressing HER2 in the mammary glands develop tumors only after acquisition of activating mutations in the transgene. In contrast, we show that expression of 611-CTF led to development of aggressive and invasive mammary tumors without the need for mutations. These results demonstrate that 611-CTF is a potent oncogene capable of promoting mammary tumor progression and metastasis.
Collapse
|
120
|
Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY, Bilous M, Dowsett M. Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients. J Clin Oncol 2009; 27:1694-705. [DOI: 10.1200/jco.2008.17.3989] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
The human epidermal receptor-2 (HER-2) is overexpressed or amplified in 15% to 25% of breast cancers. Determination of HER-2 tumor status offers clinically useful information, as it selects patients who may benefit from treatment with trastuzumab, the monoclonal antibody against HER-2. Currently approved methods for HER-2 testing include immunohistochemistry or fluorescent in situ hybridization using tumor tissue. A fragment of HER-2 composed of its extracellular domain (ECD) can also be detected in the serum of some patients with breast cancer. As an easily accessible tumor marker, it could offer additional useful prognostic or predictive information. This review will briefly address the biology of the circulating HER-2 ECD and discuss the evidence to support the role, if any, for measuring HER-2 ECD levels in women with breast cancer. In particular, we focus on the value and limitations of serum ECD in both early and advanced breast cancer in the following clinical contexts: as a marker of HER-2 tumor tissue status; clinical implications of raised levels in women who have a tumor not overexpressing HER-2; as a prognostic indicator and as a predictor of response to treatment; and as a monitoring tool for early recurrence. On the basis of our review of the literature, we conclude that there is currently insufficient evidence to support the use of serum HER-2 ECD in the routine management of individual patients with breast cancer. This conclusion is in agreement with the 2007 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer.
Collapse
Affiliation(s)
- Alexandra F. Leary
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| | - Wedad M. Hanna
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| | - Marc J. van de Vijver
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| | - Frederique Penault-Llorca
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| | - Josef Rüschoff
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| | - Robert Y. Osamura
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| | - Michael Bilous
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| | - Mitch Dowsett
- From the Royal Marsden Hospital, London, United Kingdom; Sunnybrook and Women's College, Health Science Center, Toronto, Canada; Netherlands Cancer Institute, Amsterdam, the Netherlands; Centre Jean Perrin, Clermont-Ferrand, France; Klinikum Kassel, Kassel, Germany; Tokai University School of Medicine, Kanagawa, Japan; and Westmead Hospital, Westmead, New South Wales, Australia
| |
Collapse
|
121
|
Tomasello G, de Azambuja E, Dinh P, Snoj N, Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 2009; 8:1883-90. [PMID: 19046108 DOI: 10.1586/14737140.8.12.1883] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Trastuzumab, a humanized monoclonal antibody directed against HER2, used alone or in combination with chemotherapy, has shown significant clinical benefit in improving survival in the metastatic setting, as well as halving the recurrence rate and improving survival in HER2-positive early breast cancer. Lapatinib is an orally active, reversible, small-molecule tyrosine kinase inhibitor that potently inhibits both HER1 and HER2 tyrosine kinase activity. This agent is the most advanced in terms of clinical trials and has been shown to have a favorable safety profile. Owing to the promising activity seen in advanced breast cancer, lapatinib is the ideal candidate for testing in the adjuvant setting. Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (ALTTO) is a four-arm randomized trial designed to compare trastuzumab and lapatinib in women with early-stage HER2-positive breast cancer. Specifically, ALTTO will examine which anti-HER2 agent is more effective and which is their best schedule of administration, namely, what benefit will be derived by taking the drugs separately, in tandem order or in combination. Overall, 8000 patients will be enrolled worldwide.
Collapse
Affiliation(s)
- Gianluca Tomasello
- Institute Jules Bordet, Université Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
| | | | | | | | | |
Collapse
|
122
|
SNYDER RD, BOYLE FM, CHAN A, CRAFT PS, BOER RDE, MAINWARING PN, McCARTHY NJ, WILCKEN NR. Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. Asia Pac J Clin Oncol 2009. [DOI: 10.1111/j.1743-7563.2009.01194.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
123
|
Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia 2009; 14:55-66. [PMID: 19259796 DOI: 10.1007/s10911-009-9116-x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2009] [Accepted: 02/10/2009] [Indexed: 01/07/2023] Open
Abstract
Although the development of trastuzumab and lapatinib has improved the outlook for women with HER-2 positive breast cancer, resistance to HER-2 targeted therapy is a growing clinical dilemma. Recent evidence indicates that the HER-2 pathway may play an important role in the maintenance of cancer stem cells (CSCs). The success of HER-2 targeted therapies may, in part, be explained by their direct activity against HER-2 positive CSCs. Our understanding of the mechanisms involved in resistance to trastuzumab, including loss or blockade of the trastuzumab binding site, activation of alternative signaling pathways, and induction of epithelial-mesenchymal transition (EMT), suggests that CSCs may be at the root of resistance of HER-2 targeted therapy. A variety of novel HER-2 targeted approaches have demonstrated promising preliminary clinical activity. Future clinical trials should involve the integration of technologies to assess the impact of novel HER-2 targeted therapies on HER-2 positive CSCs.
Collapse
Affiliation(s)
- Philippe L Bedard
- Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
| | | | | |
Collapse
|
124
|
Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, Forster JK, Rubin SD, Stein SH, Burstein HJ. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009; 20:1026-31. [PMID: 19179558 DOI: 10.1093/annonc/mdn759] [Citation(s) in RCA: 120] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
BACKGROUND This phase II study evaluated the efficacy and safety of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer that progressed during prior trastuzumab therapy. PATIENTS AND METHODS Women with stage IIIB/IV HER2-overexpressing breast cancer were treated with single-agent lapatinib 1250 or 1500 mg once daily after protocol amendment. Tumor response according to RECIST was assessed every 8 weeks. HER2 expression was assessed in tumor tissue by immunohistochemistry and FISH. RESULTS Seventy-eight patients were enrolled in the study. Investigator and independent review response rates [complete response (CR) or partial response (PR)] were 7.7% and 5.1%, and clinical benefit rates (CR, PR, or stable disease for >or=24 weeks) were 14.1% and 9.0%, respectively. Median time to progression was 15.3 weeks by independent review, and median overall survival was 79 weeks. The most common treatment-related adverse events were rash (47%), diarrhea (46%), nausea (31%), and fatigue (18%). CONCLUSIONS Single-agent lapatinib has clinical activity with manageable toxic effects in HER2-overexpressing breast cancer that progressed on trastuzumab-containing therapy. Studies of lapatinib-based combination regimens with chemotherapy and other targeted therapies in metastatic and earlier stages of breast cancer are warranted.
Collapse
Affiliation(s)
- K L Blackwell
- Department of Medicine/Medical Oncology, Duke University Medical Center, Durham, NC 27710, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
125
|
Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother 2009; 9:2583-601. [PMID: 18803447 DOI: 10.1517/14656566.9.15.2583] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND The recognition achieved in the late 1980s of human epidermal growth factor receptor 2 as an appealing therapeutic target for breast cancer has led to the development of targeted therapies for patients with human epidermal growth factor receptor 2-overexpressing breast tumors. OBJECTIVES The aim of the present review is to address the standard treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer patients, which is currently based on the humanized monoclonal antibody trastuzumab and to describe the new treatment options available for patients progressing on trastuzumab-based therapies. METHODS A broad literature research was performed in order to review treatments, starting from the developmental phase of trastuzumab to the most recent biologic agents being tested in human epidermal growth factor receptor 2-positive disease. RESULTS Trastuzumab combined with a taxane represents the first therapeutic option for human epidermal growth factor receptor 2-positive metastatic breast cancer. However, novel combinations of trastuzumab and chemotherapy still hold great interest for their remarkable activity and good tolerability. On the other hand, the dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor lapatinib has been the first drug to be approved in combination with capecitabine for the treatment of patients who progress on trastuzumab-based therapies. Moreover, in the near future, trastuzumab plus another biologic agent targeting human epidermal growth factor receptor 2, either directly or indirectly, may represent an effective 'chemotherapy-free' combination for trastuzumab-refractory patients.
Collapse
Affiliation(s)
- Giulio Metro
- Regina Elena Cancer Institute, Division of Medical Oncology A, Via Elio Chianesi, 53, 00144 Rome, Italy
| | | | | |
Collapse
|
126
|
Park JW, Neve RM, Szollosi J, Benz CC. Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 2008; 8:392-401. [PMID: 18952552 DOI: 10.3816/cbc.2008.n.047] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
It has been over 20 years since the discovery of the human epidermal growth factor receptor 2 (HER2), a tyrosine kinase receptor that is a potent oncoprotein in breast and other cancers and has become an opportune target for therapy. HER2 plays a critical role in normal development, forming homodimers or heterodimers with other HER family members and triggering downstream signaling cascades controlling proliferation, cell survival, and apoptosis. However, amplification of the HER2 gene in cancer cells results in overexpression of HER2 receptors on the cell surface, leading to excessive and dysregulated signaling. HER2-driven signaling also upregulates transcription factors that act on the HER2 promoter, increasing its expression. In breast cancer, HER2 is gene amplified in 20%-25% of primary tumors and is associated with a more aggressive phenotype and poorer prognosis. The key role HER2 plays in tumorigenesis makes it an ideal target for therapy. Trastuzumab, a monoclonal antibody against HER2, inhibits downstream signaling and has proven to be effective against HER2-overexpressing metastatic breast cancer both as a single agent and in combination with chemotherapy. Seminal clinical trial data also show that the use of adjuvant trastuzumab in combination with chemotherapy or as a single agent after chemotherapy significantly increases disease-free and overall survival. Lapatinib, a dual tyrosine kinase inhibitor against HER1 and HER2, has been approved in combination with capecitabine for HER2-overexpressing advanced or metastatic breast cancer, which has progressed following previous anthracycline, taxane, and trastuzumab therapy. Other HER2-targeting strategies are also under active investigation.
Collapse
Affiliation(s)
- John W Park
- Comprehensive Cancer Center, University of California, San Francisco, CA 94115-1710, USA.
| | | | | | | |
Collapse
|
127
|
Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 2008; 14:6730-4. [PMID: 18980964 DOI: 10.1158/1078-0432.ccr-08-0581] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Breast cancers overexpressing the ErbB2 (HER2) receptor tyrosine kinase oncogene are treated with targeted therapies such as trastuzumab (Herceptin), an anti-ErbB2 antibody, and lapatinib (GW572016/Tykerb), a selective small molecule inhibitor of ErbB2 and epidermal growth factor receptor tyrosine kinases that was recently approved for ErbB2+ breast cancers that progressed on trastuzumab-based therapy. The efficacy of lapatinib as a monotherapy or in combination with chemotherapy, however, is limited by the development of therapeutic resistance that typically occurs within 12 months of starting therapy. In contrast to small molecule inhibitors targeting other receptor tyrosine kinases where resistance has been attributed to mutations within the targeted receptor, ErbB2 mutations have not been commonly found in breast tumors. Instead, acquired resistance to lapatinib seems to be mediated by redundant survival pathways that are activated as a consequence of marked inhibition of ErbB2 kinase activity. For example, inhibition of phosphatidylinositol3 kinase-Akt in lapatinib-treated cells leads to derepression of FOXO3A, a transcription factor that up-regulates estrogen receptor (ER) signaling, resulting in a switch in the regulation of survival factors (e.g., survivin) and cell survival from ErbB2 alone to ER and ErbB2 in resistant cells. In this review, we discuss the effects of lapatinib on signaling networks in ErbB2+ breast cancer cells to elucidate potential mechanisms of therapeutic resistance and strategies to overcome or prevent its development.
Collapse
Affiliation(s)
- Franklin L Chen
- Duke University Medical Center, Department of Medicine, Division of Medical Oncology, Durham, North Carolina 27710, USA
| | | | | |
Collapse
|
128
|
Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:485-98. [PMID: 19034632 DOI: 10.1007/s10911-008-9107-3] [Citation(s) in RCA: 117] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2008] [Accepted: 11/13/2008] [Indexed: 12/15/2022] Open
Abstract
Understanding the molecular mechanisms involved in tumorigenesis and their influence on clinical outcome is providing specific molecular markers for targeted therapy. Activation of tyrosine kinase receptors from the human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4) and the insulin-like growth factor receptor I (IGF-IR) plays a key role in the initiation and progression of breast cancer. HER2 overexpression is a validated therapeutic target, as shown by the clinical efficacy of trastuzumab and lapatinib. However, only 25-30% of patients with HER2-overexpressing tumors respond to single-agent trastuzumab or lapatinib, and resistance develops even in responding patients. Therefore, to optimize therapeutic efficacy, it is urgent to elucidate the complex network of signaling pathways that develop in breast cancer cells. Signaling interactions have been reported between ErbB/HER family members and IGF-IR. As increased IGF-IR signaling has been implicated in trastuzumab resistance, agents targeting HER2, and IGF-IR could be potential therapeutic tools in breast cancers that develop resistance to HER2-directed therapy.
Collapse
Affiliation(s)
- Quanri Jin
- Departments of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
| | | |
Collapse
|
129
|
Nakagawa K, Minami H, Kanezaki M, Mukaiyama A, Minamide Y, Uejima H, Kurata T, Nogami T, Kawada K, Mukai H, Sasaki Y, Fukuoka M. Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors. Jpn J Clin Oncol 2008; 39:116-23. [DOI: 10.1093/jjco/hyn135] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
|
130
|
Pegram M. Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? Clin Breast Cancer 2008; 8 Suppl 3:S121-30. [PMID: 18777951 DOI: 10.3816/cbc.2008.s.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The recent development of targeted therapies using monoclonal antibodies has added new dimensions to the rapidly evolving field of breast cancer treatment. In particular, the incorporation of trastuzumab into regimens containing existing chemotherapeutic agents has significantly improved clinical outcomes for patients with breast cancer in the adjuvant and metastatic settings. De novo and acquired resistance to this treatment, however, is widespread. A substantial amount of research has therefore been dedicated to the elucidation of molecular mechanisms that could explain resistance to this otherwise effective therapy. Potential mechanisms for resistance to trastuzumab include steric inhibition imposed by other extracellular factors, molecular changes in the target receptor itself (ErbB2), alterations in the regulation of downstream signaling components, and crosstalk with other pathways that could compensate for attenuated ErbB2 signaling. In addition, preclinical and clinical studies have been performed to identify potential methods for overcoming trastuzumab resistance, including targeting alternate ErbB2 epitopes and the combined inhibition of multiple signaling components and/or pathways (vertical or horizontal inhibition). Studies continue to evaluate the most promising approaches for overcoming mechanisms of resistance to trastuzumab and other ErbB2-targeted therapies. This review will summarize the most recent research designed to address this substantial clinical problem and provide clinicians with relevant background for understanding some of the potential molecular mechanisms for resistance to targeted therapies in the treatment of patients with breast cancer.
Collapse
Affiliation(s)
- Mark Pegram
- Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
| |
Collapse
|
131
|
Guarneri V, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte P. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial). Clin Breast Cancer 2008; 8:192-4. [PMID: 18621618 DOI: 10.3816/cbc.2008.n.022] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Valentina Guarneri
- Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, University of Modena and Reggio Emilia, Modena, Italy
| | | | | | | | | | | | | |
Collapse
|
132
|
Wysocki PJ, Wysocki H. Cardiovascular complications associated with biological therapies for breast cancer. Expert Opin Biol Ther 2008; 8:1551-9. [DOI: 10.1517/14712598.8.10.1551] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
133
|
Dawood S, Resetkova E, Gonzalez-Angulo AM. Trastuzumab Administration Associated with Change in HER2 Status. Clin Breast Cancer 2008; 8:366-9. [DOI: 10.3816/cbc.2008.n.044] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
134
|
Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA. Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. J Clin Oncol 2008; 26:3317-23. [DOI: 10.1200/jco.2007.13.5202] [Citation(s) in RCA: 98] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The combination of lapatinib and trastuzumab has been observed to have a synergistic, antiproliferative effect against ErbB2-positive breast cancer cells in vitro. This phase I study assessed the safety, clinical feasibility, optimally tolerated regimen (OTR), pharmacokinetics (PK), and preliminary clinical activity of this combination in patients with ErbB2-positive advanced breast cancer. Patients and Methods Cohorts of three patients with ErbB2-positive advanced breast cancer were treated with escalating doses of lapatinib (750 to 1,500 mg) administered once daily (continuous) in combination with trastuzumab (4 mg/kg loading dose then 2 mg/kg weekly) to determine the OTR. Once the OTR was determined, additional patients were enrolled to provide the PK profile of both agents alone and in combination. Results A total of 54 patients were treated: 27 in the dose-escalation group and 27 in the PK group. Overall, adverse events were mild to moderate in severity, with no drug-related grade 4 events. The most frequent drug-related grade 3 events included diarrhea (17%), fatigue (11%), and rash (6%). The OTR was 1,000 mg lapatinib with standard weekly trastuzumab. One patient had a complete response and seven patients had partial responses. The PK parameters (maximum concentration in plasma and area under the curve) of lapatinib and trastuzumab in combination were not significantly different than when either was administered alone. Conclusion The OTR of the lapatinib/trastuzumab combination was lapatinib 1,000 mg per day with standard weekly trastuzumab. At these doses, the regimen was well tolerated and clinically active in this heavily pretreated ErbB2-positive breast cancer population.
Collapse
Affiliation(s)
- Anna Maria Storniolo
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Mark D. Pegram
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Beth Overmoyer
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Paula Silverman
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Nancy W. Peacock
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Suzanne F. Jones
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Jill Loftiss
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Nikita Arya
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Kevin M. Koch
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Elaine Paul
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Lini Pandite
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Ronald A. Fleming
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Peter F. Lebowitz
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Peter T.C. Ho
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| | - Howard A. Burris
- From the Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sarah Cannon Research Institute, Nashville, TN; UCLA Center for the Health Sciences, Los Angeles, CA; Northwestern CT Oncology/Hematology Associates, Torrington, CT; Ireland Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; and GlaxoSmithKline, Research Triangle Park, NC
| |
Collapse
|
135
|
Cameron DA, Stein S. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. ACTA ACUST UNITED AC 2008; 5:512-20. [PMID: 18594499 DOI: 10.1038/ncponc1156] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2007] [Accepted: 01/03/2008] [Indexed: 01/07/2023]
Abstract
Targeting the human epidermal growth factor receptor type 2 (HER2) in breast cancer patients whose tumors overexpress HER2 has been clearly demonstrated to be effective in clinical trials with the monoclonal antibody trastuzumab. Not all patients, however, respond to trastuzumab therapy. Lapatinib is an oral receptor tyrosine kinase inhibitor that targets HER2 and the EGFR. Preclinical data reveal that lapatinib has activity in trastuzumab-resistant cell lines as well as synergistic activity with trastuzumab. In a pivotal phase III trial, a combination of lapatinib and capecitabine significantly decreased the risk of disease progression relative to capecitabine alone in women with HER2-positive advanced or metastatic breast cancer previously treated with anthracyclines, taxanes, and trastuzumab. Other trials are evaluating lapatinib in inflammatory breast cancer--for which encouraging data have been reported--in combination with hormone therapy, in combination with trastuzumab, and as an adjunct to adjuvant therapy for early-stage disease. Notably, lapatinib has not been associated with serious or symptomatic cardiotoxicity in clinical trials. It can cross the blood-brain barrier and might therefore have a role in preventing central-nervous-system progression. These features make lapatinib an ideal agent to evaluate more fully in HER2-positive metastatic and early-stage breast cancer.
Collapse
Affiliation(s)
- David A Cameron
- DA Cameron is Professor of Medical Oncology and NCRN Director at the NCRN Co-ordinating Centre, Leeds, UK
| | | |
Collapse
|
136
|
Burstein H, Storniolo A, Franco S, Forster J, Stein S, Rubin S, Salazar V, Blackwell K. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19:1068-74. [DOI: 10.1093/annonc/mdm601] [Citation(s) in RCA: 169] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
137
|
Harbeck N, Heinemann V, Loibl S, Untch M. Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer. Breast Care (Basel) 2008; 3:7-12. [PMID: 20824002 PMCID: PMC2930990 DOI: 10.1159/000119744] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Nadia Harbeck
- Frauenklinik der Technischen Universität München, Klinikum Rechts der Isar, Berlin, Germany
| | - Volker Heinemann
- Med. Klinik und Poliklinik III, Klinikum Großhadern der Ludwig-Maximilians-Universität München, Berlin, Germany
| | | | - Michael Untch
- HELIOS Klinikum Berlin-Buch, Klinikum Buch – Frauenklinik, Berlin, Germany
| |
Collapse
|
138
|
Abstract
Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.
Collapse
|
139
|
Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008; 15:413-48. [PMID: 18404164 DOI: 10.1038/cgt.2008.15] [Citation(s) in RCA: 180] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
ERBB3, a member of the epidermal growth factor receptor (EGFR) family, is unique in that its tyrosine kinase domain is functionally defective. It is activated by neuregulins, by other ERBB and nonERBB receptors as well as by other kinases, and by novel mechanisms. Downstream it interacts prominently with the phosphoinositol 3-kinase/AKT survival/mitogenic pathway, but also with GRB, SHC, SRC, ABL, rasGAP, SYK and the transcription regulator EBP1. There are likely important but poorly understood roles for nuclear localization and for secreted isoforms. Studies of ERBB3 expression in primary cancers and of its mechanistic contributions in cultured cells have implicated it, with varying degrees of certainty, with causation or sustenance of cancers of the breast, ovary, prostate, certain brain cells, retina, melanocytes, colon, pancreas, stomach, oral cavity and lung. Recent results link high ERBB3 activity with escape from therapy targeting other ERBBs in lung and breast cancers. Thus a wide and centrally important role for ERBB3 in cancer is becoming increasingly apparent. Several approaches for targeting ERBB3 in cancers have been tested or proposed. Small inhibitory RNA (siRNA) to ERBB3 or AKT is showing promise as a therapeutic approach to treatment of lung adenocarcinoma.
Collapse
|
140
|
Higa GM. Targeting HER 1 and 2 in breast cancer with lapatinib. Oncol Rev 2008. [DOI: 10.1007/s12156-008-0052-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
141
|
Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE, Salazar V, Zaks TZ, Spector NL. Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy. J Clin Oncol 2008; 26:1066-72. [DOI: 10.1200/jco.2007.13.9949] [Citation(s) in RCA: 161] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Purpose Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor (EGFR) and human EGFR 2 (HER-2), demonstrated clinical activity in four of five IBC patients in phase I trials. We conducted a phase II trial to confirm the sensitivity of IBC to lapatinib, to determine whether response is HER-2 or EGFR dependent, and to elucidate a molecular signature predictive of lapatinib sensitivity. Patients and Methods Our open-label multicenter phase II trial (EGF103009) assessed clinical activity and safety of lapatinib monotherapy in patients with recurrent or anthracycline-refractory IBC. Patients were assigned to cohorts A (HER-2–overexpressing [HER-2+]) or B(HER-2–/EGFR+) and fresh pretreatment tumor biopsies were collected. Results Forty-five patients (30 in cohort A; 15 in cohort B) received lapatinib 1,500 mg once daily continuously. Clinical presentation and biomarker analyses demonstrated a tumor molecular signature consistent with IBC. Lapatinib was generally well tolerated, with primarily grade 1/2 skin and GI toxicities. Fifteen patients (50%) in cohort A had clinical responses to lapatinib in skin and/or measurable disease (according to Response Evaluation Criteria in Solid Tumors) compared with one patient in cohort B. Within cohort A, phosphorylated (p) HER-3 and lack of p53 expression predicted for response to lapatinib (P < .05). Tumors coexpressing pHER-2 and pHER-3 were more likely to respond to lapatinib (nine of 10 v four of 14; P = .0045). Prior trastuzumab therapy and loss of phosphate and tensin homolog 10 (PTEN) did not preclude response to lapatinib. Conclusion Lapatinib is well tolerated with clinical activity in heavily pretreated HER-2+, but not EGFR+/HER-2–, IBC. In this study, coexpression of pHER-2 and pHER-3 in tumors seems to predict for a favorable response to lapatinib. These findings warrant further investigation of lapatinib monotherapy or combination therapy in HER-2+ IBC.
Collapse
Affiliation(s)
- Stephen Johnston
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Maureen Trudeau
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Bella Kaufman
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Hamouda Boussen
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Kimberley Blackwell
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Patricia LoRusso
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Donald P. Lombardi
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Slim Ben Ahmed
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Dennis L. Citrin
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Michelle L. DeSilvio
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Jennifer Harris
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Ron E. Westlund
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Vanessa Salazar
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Tal Z. Zaks
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| | - Neil L. Spector
- From the Department of Medicine-Breast Unit, Royal Marsden Hospital, London, United Kingdom; Medical Oncology & Hematology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada; Oncology Institute, The Chaim Sheba Medical Center, Tel Hashomer, Israel; Institut Shalah Azaiz, Tunis; Department of Service de Carcinologie Médicale, CHU Farhat Hached, Sousse, Tunisia; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Detroit, MI; Washington University Medical
| |
Collapse
|
142
|
Piccart M. Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer. Clin Breast Cancer 2008; 8 Suppl 3:S100-13. [DOI: 10.3816/cbc.2008.s.006] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
143
|
|
144
|
Pegram M, Perez EA, Piccart M, Spector N. Expert Roundtable: Emerging Questions in ErbB2-Positive Breast Cancer; February 22, 2007. Clin Breast Cancer 2008; 8 Suppl 3:S131-41. [DOI: 10.3816/cbc.2008.s.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
145
|
Whenham N, D'Hondt V, Piccart MJ. HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies. Clin Breast Cancer 2008; 8:38-49. [DOI: 10.3816/cbc.2008.n.002] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
146
|
Janni W, von Minckwitz G, Möbus V, Nitz U. Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer. Breast Care (Basel) 2008; 3:17-20. [PMID: 20824004 DOI: 10.1159/000119747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- Wolfgang Janni
- Klinikum der LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Innenstadt, München, Germany
| | | | | | | |
Collapse
|
147
|
Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. Ann Oncol 2007; 18 Suppl 6:vi26-30. [PMID: 17591827 DOI: 10.1093/annonc/mdm220] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Aberrant activation of some members of human epidermal growth factor receptor (HER) family plays a key role in breast carcinogenesis. Lapatinib is an oral dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR/ErbB1) and HER2/ErbB2. Having more targets, probably its antitumor activity could be more efficient. Clinical data have shown that lapatinib is active in HER2-positive breast cancer as monotherapy, in combination with trastuzumab, and in trastuzumab-resistant patients. Phase I clinical trials have shown also that lapatinib is well tolerated, with mild diarrhea and skin rush as common toxic effects and low incidence of cardiotoxicity. Phase II and III clinical trials' data provide encouraging evidence of the clinical effectiveness of lapatinib in advanced or metastatic breast cancer and for its potential in patients with brain metastases. Interim results from the large, phase III trial in 392 patients showed that in combination with capecitabine lapatinib almost doubled time to progression when compared with capecitabine alone. Several clinical trials that explore the efficacy of lapatinib in combination with conventional chemotherapeutic agents [paclitaxel (Taxol), capecitabine and platinoids], hormonotherapy and other target therapies are ongoing in advanced breast cancer or in neo-adjuvant and adjuvant settings. Our improved understanding of the biology of breast cancer and the use of biomarkers for identification of specific subtypes are allowing us to bring patient-specific novel therapies such as lapatinib to the clinic.
Collapse
Affiliation(s)
- D Bilancia
- Medical Oncology Unit, San Carlo Hospital, Potenza, Italy.
| | | | | | | | | | | |
Collapse
|
148
|
Mukherjee A, Dhadda AS, Shehata M, Chan S. Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer. Expert Opin Pharmacother 2007; 8:2189-204. [PMID: 17714070 DOI: 10.1517/14656566.8.13.2189] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapatinib from preclinical studies to the pivotal Phase III trial and ongoing clinical studies. Areas of interest include the advantages of small molecule TKIs versus antibodies in targeting HER receptors and the efficacy of lapatinib in the treatment of cerebral metastases. The surprisingly high response rate in inflammatory breast cancer raises the possibility of other novel predictive biomarkers. The potential for combination and sequencing with other biological and cytotoxic agents is both exciting and challenging.
Collapse
Affiliation(s)
- A Mukherjee
- Nottingham University Hospitals NHS Trust (City Hospital Campus), Department of Clinical Oncology, Nottingham, UK.
| | | | | | | |
Collapse
|
149
|
Widakowich C, de Azambuja E, Gil T, Cardoso F, Dinh P, Awada A, Piccart-Gebhart M. Molecular targeted therapies in breast cancer: Where are we now? Int J Biochem Cell Biol 2007; 39:1375-87. [PMID: 17543572 DOI: 10.1016/j.biocel.2007.04.015] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2007] [Accepted: 04/16/2007] [Indexed: 12/30/2022]
Abstract
Targeted therapies, in cancer treatment, represent a new generation of drugs that interfere with specific molecular targets (typically proteins) having critical roles to play in tumour growth or progression. The principle of targeted therapy is certainly not new: tamoxifen, a hormonal agent targeted at the estrogen receptor, has been in use for more than 30 years. However, this principle has re-gained significant emphasis with the recent development of new biological agents, such as trastuzumab, which was first approved for the treatment of advanced breast cancer (BC) in 1998. Presently, there are at least three different targeted therapies with well documented activity in advanced BC and all three are now being studied in the adjuvant setting; trastuzumab and bevacizumab are monoclonal antibodies, and lapatinib is a dual inhibitor of HER-1 and HER-2. This paper will review the increasing role of molecular targeted therapies in BC, with a particular focus on those drugs currently being tested in early BC, as well as, on future perspectives.
Collapse
Affiliation(s)
- Christian Widakowich
- Medical Oncology Clinic, Jules Bordet Institute, Rue Heger-Bordet 1, 1000 Brussels, Belgium
| | | | | | | | | | | | | |
Collapse
|
150
|
Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, Pry K, Hill JE, Xia W, Seger R, Bacus SS. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A 2007; 104:10607-12. [PMID: 17556544 PMCID: PMC1965560 DOI: 10.1073/pnas.0701286104] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
The human EGF receptor (HER) 2 receptor tyrosine kinase is a survival factor for human cardiomyocytes, and its inhibition may explain the increased incidence of cardiomyopathy associated with the anti-HER2 monoclonal antibody trastuzumab (Genentech, South San Francisco, CA), particularly in patients with prior exposure to cardiotoxic chemotherapies e.g., anthracyclines. Here, we show that GW2974 (HER2/EGF receptor tyrosine kinase inhibitor), but not trastuzumab, activates AMP-activated protein kinase (AMPK), initiating a metabolic stress response in human cardiomyocytes that protects against TNFalpha-induced cell death. GW2974 stimulates calcium dependent fatty acid oxidation in vitro and in the myocardium of GW2974-treated rodents. Calcium chelation or siRNA-targeted AMPK knockdown blocks GW2974 induced fatty acid oxidation. In addition, inhibition of AMPK by a specific inhibitor resulted in increased killing of cardiomyocytes. Elucidating the effects of HER2-targeted therapies on AMPK may predict for risk of cardiomyopathy and provide a novel HER2-targeted strategy designed to protect myocardium from the pro-apoptotic effects of pro-inflammatory cytokines released in response to cardiac injury by chemotherapy or acute ischemia.
Collapse
Affiliation(s)
- Neil L. Spector
- *Duke Comprehensive Cancer Center, Duke University Medical Center, 106 Research Drive, Medical Science Research Building II, Durham, NC 27710
| | - Yosef Yarden
- Department of Biological Regulation, Weizmann Institute, Room 302, Candiotty Building, 1 Hertzl Street, 76100 Rehovot, Israel
| | - Bradley Smith
- Cell Signaling Technologies, 166B Cummings Center, Beverly, MA 01945; and
| | - Ljuba Lyass
- Targeted Molecular Diagnostics, 610 Oakmont Lane, Westmont, IL 60559
| | - Patricia Trusk
- Targeted Molecular Diagnostics, 610 Oakmont Lane, Westmont, IL 60559
| | - Karen Pry
- Targeted Molecular Diagnostics, 610 Oakmont Lane, Westmont, IL 60559
| | - Jason E. Hill
- Targeted Molecular Diagnostics, 610 Oakmont Lane, Westmont, IL 60559
| | - Wenle Xia
- *Duke Comprehensive Cancer Center, Duke University Medical Center, 106 Research Drive, Medical Science Research Building II, Durham, NC 27710
| | - Rony Seger
- Department of Biological Regulation, Weizmann Institute, Room 302, Candiotty Building, 1 Hertzl Street, 76100 Rehovot, Israel
| | - Sarah S. Bacus
- Targeted Molecular Diagnostics, 610 Oakmont Lane, Westmont, IL 60559
- To whom correspondence should be addressed. E-mail:
| |
Collapse
|